US Stock MarketDetailed Quotes

BLRX BioLine Rx

Watchlist

0.323
-0.222-40.71%

Close Nov 21 16:00 ET

0.325
+0.002+0.54%

Post 20:01 ET

25.84MMarket Cap-713P/E (TTM)

BioLine Rx Stock Forum

Trytosaveabit

18 hours ago

Hehehe! Here’s the rest!

$BioLine Rx (BLRX.US)$ BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous...

Trytosaveabit

18 hours ago

Hmm! News

$BioLine Rx (BLRX.US)$ Reuters· 1 min ago
BioLine RX Ltd - Biolinerx to Receive $10 Mln Upfront, up to $87 Mln in Milestones

13112024

20 hours ago

$BioLine Rx (BLRX.US)$ all leaving, too expensive sell more than $1

Jaguar8

Nov 5 08:02

NEWS

$BioLine Rx (BLRX.US)$
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
BioLineRx (NASDAQ: BLRX) announced positive initial results from a Phase 1 clinical trial evaluating motixafortide for stem cell mobilization in sickle cell disease (SCD) gene therapies. The study showed that motixafortide, both alone and combined with natalizumab, was safe...

Trytosaveabit

Oct 16 06:18

News

$BioLine Rx (BLRX.US)$ BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide

Keith Squires

Aug 30 10:17

$BioLine Rx (BLRX.US)$ only see this stock rising anywhere from $6-$13 to $21 from now to early next year.iam going to be right on this one so you all can buy me a new truck,hold moo mooers

Blue Coffee Brewing

Jul 31 09:57

Make the best use of the Features!

There are many features available and sometimes I use interpretation of indicator to have a quick decision filter to decide if should further look at the potential investment opportunity!

Q2 earnings challenge: Ride the market wave with moomoo

Trytosaveabit

May 30 06:13

Update

$BioLine Rx (BLRX.US)$ Benzinga· 1 min ago
BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

Trytosaveabit

May 6 06:07

Watching for data!

$BioLine Rx (BLRX.US)$ BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024

Trytosaveabit

Apr 10 06:15

Update

$BioLine Rx (BLRX.US)$ BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data